Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.

Chen, Ting; Xie, Ruixiang; Zhao, Qiuling; Cai, Hongfu; Yang, Lin

Chen, Ting; Xie, Ruixiang; Zhao, Qiuling; Cai, Hongfu; Yang, Lin.

Afiliación

Chen T; Department of Pharmacy, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Xie R; Department of Pharmacy, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Zhao Q; Department of Pharmacy, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Cai H; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
Yang L; Department of Pharmacy, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.

Front Oncol ; 12: 746526, 2022.

Article en En | MEDLINE | ID: mdl-35936702

Palabras clave

camrelizumab; chemotherapy; cost-utility analysis; first-line treatment; nonsquamous NSCLC

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google